| Style | Citing Format |
|---|---|
| MLA | Daneshpazhooh M, et al.. "Iranian Guideline for Rituximab Therapy in Pemphigus Patients." Dermatologic Therapy, vol. 32, no. 5, 2019, pp. -. |
| APA | Daneshpazhooh M, Balighi K, Mahmoudi H, Tavakolpour S, Abedini R, Soori T, Ehsani AH, Ghiasi M, Noormohammadpour P, Ghandi N, Lajevardi V, Sadeghinia A, Nasimi M, Azizpour A, Chamsdavatchi C (2019). Iranian Guideline for Rituximab Therapy in Pemphigus Patients. Dermatologic Therapy, 32(5), -. |
| Chicago | Daneshpazhooh M, Balighi K, Mahmoudi H, Tavakolpour S, Abedini R, Soori T, Ehsani AH, et al.. "Iranian Guideline for Rituximab Therapy in Pemphigus Patients." Dermatologic Therapy 32, no. 5 (2019): -. |
| Harvard | Daneshpazhooh M et al. (2019) 'Iranian Guideline for Rituximab Therapy in Pemphigus Patients', Dermatologic Therapy, 32(5), pp. -. |
| Vancouver | Daneshpazhooh M, Balighi K, Mahmoudi H, Tavakolpour S, Abedini R, Soori T, et al.. Iranian Guideline for Rituximab Therapy in Pemphigus Patients. Dermatologic Therapy. 2019;32(5):-. |
| BibTex | @article{ author = {Daneshpazhooh M and Balighi K and Mahmoudi H and Tavakolpour S and Abedini R and Soori T and Ehsani AH and Ghiasi M and Noormohammadpour P and Ghandi N and Lajevardi V and Sadeghinia A and Nasimi M and Azizpour A and Chamsdavatchi C}, title = {Iranian Guideline for Rituximab Therapy in Pemphigus Patients}, journal = {Dermatologic Therapy}, volume = {32}, number = {5}, pages = {-}, year = {2019} } |
| RIS | TY - JOUR AU - Daneshpazhooh M AU - Balighi K AU - Mahmoudi H AU - Tavakolpour S AU - Abedini R AU - Soori T AU - Ehsani AH AU - Ghiasi M AU - Noormohammadpour P AU - Ghandi N AU - Lajevardi V AU - Sadeghinia A AU - Nasimi M AU - Azizpour A AU - Chamsdavatchi C TI - Iranian Guideline for Rituximab Therapy in Pemphigus Patients JO - Dermatologic Therapy VL - 32 IS - 5 SP - EP - PY - 2019 ER - |